REGENXBIO Inc.

ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ —  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA. The presentations will highlight new data for ABBV-RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment … Read more

ROCKVILLE, Md., June 1, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023. Jefferies Global Healthcare ConferenceDate: Thursday, June 8, 2023Presentation: 1:30 p.m. ET A live webcast of the presentation can be accessed in the Investors section of … Read more

ROCKVILLE, Md., May 22, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023. Barclays Gene Editing & Therapy Summit 2023Date: Wednesday, May 24, 2023Fireside Chat: 9:15 … Read more

Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development of gene therapies for rare diseases ROCKVILLE, Md., May 16, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for … Read more